Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Mice received interleukin-2 (IL-2) either before and after, or just after intravenous inoculation of syngeneic fibrosarcoma cells. Fewer pulmonary tumor colonies were observed in those animals treated with IL-2, and the best results were observed when IL-2 was administered prior to tumor inoculation. When mice were lethally irradiated and reconstituted with tumor-contaminated bone marrow, IL-2 treatment was also associated with fewer tumor lung colonies. IL-2 may prove to be a useful adjuvant therapy, particularly in the setting of autologous bone marrow transplantation when the infused marrow is contaminated with tumor cells.
Ho
S P
SP
Department of Medicine, University of Wisconsin-Madison.
Stebler
B
B
Ershler
W B
WB
D000818:Animals; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003601:Cytotoxicity Tests, Immunologic; D004195:Disease Models, Animal; D005260:Female; D005354:Fibrosarcoma / Q000556:secondary / Q000628:therapy*; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D012016:Reference Values; D014185:Transplantation, Isogeneic
D007376:Interleukin-2